© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to July
covalent immunoproteasome inhibitor
subcutaneous agent in Ph. I/II for SLE and LN
designed from proteasome inhibitors
Drug Metabolism and Disposition
Kezar Life Sciences, San Francisco, US
The Kezar Life Sciences covalent immunoproteasome inhibitor, KZR-616, licensed from Onyx, targets the LMP7 and LMP2 active sites of the immunoproteasome, and is currently in Ph. II trials for autoimmune disorders…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.